(Q28216230)

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin converting enzyme is located on alpha-actin filaments in smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Cloning and expression of a cDNA encoding an endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Cloning and expression of human endothelin-1 receptor cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Molecular cloning of a non-isopeptide-selective human endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin is blood vessel selective: studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effect of endothelin on renal function in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Rat renal, aortic and pulmonary endothelin-I receptors: effects of changes in sodium and water intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Salt-sensitive hypertension in endothelin-B receptor-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effect of endothelin-1 (1-31) on human mesangial cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Augmented response of endothelin-A and endothelin-B receptor stimulation in coronary arteries of hypertensive hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Role of endothelin in the increased vascular tone of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Increased endothelin excretion in rats with renal failure induced by partial nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Regression of renal vascular fibrosis by endothelin receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Effects of phosphoramidon, BQ 788, and BQ 123 on coronary and cardiac dysfunctions of the failing hamster heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Contribution of endogenous generation of endothelin-1 to basal vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001

Inhibition of myocardial endothelin pathway improves long-term survival in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.001